Elliott P Vichinsky

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2634316/publications.pdf

Version: 2024-02-01

		9264	7160
416	26,822	74	153
papers	citations	h-index	g-index

432	432	432	12297
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England Journal of Medicine, 1998, 339, 5-11.	27.0	1,699
2	Pain in Sickle Cell Disease. New England Journal of Medicine, 1991, 325, 11-16.	27.0	1,431
3	Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. New England Journal of Medicine, 2000, 342, 1855-1865.	27.0	1,062
4	Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia. New England Journal of Medicine, 1986, 314, 1593-1599.	27.0	1,048
5	Sickle cell disease. Nature Reviews Disease Primers, 2018, 4, 18010.	30.5	764
6	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	7.4	741
7	Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2005, 294, 81.	7.4	619
8	Alloimmunization in Sickle Cell Anemia and Transfusion of Racially Unmatched Blood. New England Journal of Medicine, 1990, 322, 1617-1621.	27.0	542
9	Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2018, 378, 1479-1493.	27.0	525
10	Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. Blood, 1997, 89, 1787-1792.	1.4	508
11	A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the Î²-Globin Disorders. New England Journal of Medicine, 1993, 328, 81-86.	27.0	443
12	Pulmonary Complications of Sickle Cell Disease. New England Journal of Medicine, 2008, 359, 2254-2265.	27.0	410
13	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
14	A Phase 3 Trial of<scp>l</scp>-Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235.	27.0	378
15	Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 1995, 126, 896-899.	1.8	346
16	Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood, 2002, 99, 3014-3018.	1.4	319
17	Arginine Therapy. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 63-69.	5.6	302
18	Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion, 2001, 41, 1086-1092.	1.6	296

#	Article	IF	Citations
19	Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, 2000, 96, 3369-3373.	1.4	263
20	Oxidative stress and inflammation in ironâ€overloaded patients with Î²â€thalassaemia or sickle cell disease. British Journal of Haematology, 2006, 135, 254-263.	2.5	260
21	Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 385-390.	1.8	256
22	A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 2007, 136, 501-508.	2.5	255
23	Concurrent Sickle-Cell Anemia and Î±-Thalassemia. New England Journal of Medicine, 1982, 306, 270-274.	27.0	252
24	Neuropsychologic performance in school-aged children with sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 2001, 139, 391-397.	1.8	248
25	Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2010, 303, 1823.	7.4	241
26	Non-transfusion-dependent thalassemias. Haematologica, 2013, 98, 833-844.	3.5	231
27	Stroke Prevention Trial in Sickle Cell Anemia. Contemporary Clinical Trials, 1998, 19, 110-129.	1.9	228
28	Natural History of Blood Pressure in Sickle Cell Disease: Risks for Stroke and Death Associated with Relative Hypertension in Sickle Cell Anemia. American Journal of Medicine, 1997, 102, 171-177.	1.5	224
29	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	2.2	210
30	Discontinuing penicillin prophylaxis in children with sickle cell anemia. Journal of Pediatrics, 1995, 127, 685-690.	1.8	195
31	Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem. Journal of Bone and Mineral Research, 2009, 24, 543-557.	2.8	189
32	Thalassemia. Hematology American Society of Hematology Education Program, 2004, 2004, 14-34.	2.5	181
33	Gene interactions and stroke risk in children with sickle cell anemia. Blood, 2004, 103, 2391-2396.	1.4	178
34	Changing Patterns of Thalassemia Worldwide. Annals of the New York Academy of Sciences, 2005, 1054, 18-24.	3.8	178
35	Increased prevalence of ironâ€overload associated endocrinopathy in thalassaemia versus sickleâ€cell disease. British Journal of Haematology, 2006, 135, 574-582.	2.5	178
36	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 2000, 96, 76-79.	1.4	177

#	Article	IF	Citations
37	Patterns of Arginine and Nitric Oxide in Patients With Sickle Cell Disease With Vaso-occlusive Crisis and Acute Chest Syndrome. The American Journal of Pediatric Hematology/oncology, 2000, 22, 515-520.	1.3	176
38	Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood, 2008, 111, 402-410.	1.4	157
39	Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood, 2004, 103, 3689-3694.	1.4	156
40	Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. British Journal of Haematology, 2009, 146, 546-556.	2.5	153
41	Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multiâ€center study of iron overload. American Journal of Hematology, 2007, 82, 255-265.	4.1	149
42	Newborn screening for hemoglobinopathies in California. Pediatric Blood and Cancer, 2009, 52, 486-490.	1.5	145
43	Decrease of Very Late Activation Antigen-4 and CD36 on Reticulocytes in Sickle Cell Patients Treated With Hydroxyurea. Blood, 1997, 89, 2554-2559.	1.4	139
44	Managing sickle cell disease. BMJ: British Medical Journal, 2003, 327, 1151-1155.	2.3	139
45	Heterogeneity of Hemoglobin H Disease in Childhood. New England Journal of Medicine, 2011, 364, 710-718.	27.0	136
46	Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state. American Journal of Hematology, 2006, 81, 670-675.	4.1	135
47	Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. Journal of Pediatrics, 2003, 143, 438-444.	1.8	133
48	A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica, 2013, 98, 1375-1382.	3.5	130
49	The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group. , 1999, 62, 129-138.		128
50	Comparison of organ dysfunction in transfused patients with SCD or Î² thalassemia. American Journal of Hematology, 2005, 80, 70-74.	4.1	125
51	Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with Î²-thalassemia. Clinical Therapeutics, 2007, 29, 909-917.	2.5	123
52	Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatric Blood and Cancer, 2007, 49, 329-332.	1.5	121
53	Current issues with blood transfusions in sickle cell disease. Seminars in Hematology, 2001, 38, 14-22.	3.4	115
54	Hemoglobin E Syndromes. Hematology American Society of Hematology Education Program, 2007, 2007, 79-83.	2.5	115

#	Article	IF	Citations
55	Changes in the Epidemiology of Thalassemia in North America: A New Minority Disease. Pediatrics, 2005, 116, e818-e825.	2.1	110
56	Clinical application of deferasirox: Practical patient management. American Journal of Hematology, 2008, 83, 398-402.	4.1	109
57	Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. British Journal of Haematology, 2011, 153, 121-128.	2.5	108
58	Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurology, The, 2019, 18, 631-642.	10.2	102
59	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. SHORT REPORT. British Journal of Haematology, 2000, 111, 498-500.	2.5	102
60	Efficacy and safety of deferasirox doses of >30â€ƒmg/kg per d in patients with transfusionâ€dependent anaemia and iron overload. British Journal of Haematology, 2009, 147, 752-759.	2.5	101
61	Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, 114, 4632-4638.	1.4	98
62	Transfusion complications in thalassemia patients: a report from the <scp>C</scp>enters for <scp>D</scp>isease <scp>C</scp>ontrol and <scp>P</scp>revention (CME). Transfusion, 2014, 54, 972-981.	1.6	97
63	Hemolysis-Associated Pulmonary Hypertension in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 481-485.	3.8	96
64	Using quality improvement strategies to enhance pediatric pain assessment. International Journal for Quality in Health Care, 2002, 14, 39-47.	1.8	95
65	Current issues with blood transfusions in sickle cell disease. Seminars in Hematology, 2001, 38, 14-22.	3.4	95
66	Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood, 2000, 96, 3276-3278.	1.4	92
67	Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine, 2004, 350, 857-859.	27.0	92
68	Effect of hydroxyurea on growth in children with sickle cell anemia: Results of the HUG-KIDS study. Journal of Pediatrics, 2002, 140, 225-229.	1.8	89
69	Physical Therapy Alone Compared with Core Decompression and Physical Therapy for Femoral Head Osteonecrosis in Sickle Cell Disease. Journal of Bone and Joint Surgery - Series A, 2006, 88, 2573-2582.	3.0	88
70	Universal Newborn Screening for Hb H Disease in California. Genetic Testing and Molecular Biomarkers, 2001, 5, 93-100.	1.7	87
71	Effects of a long-term transfusion regimen on sickle cell-related illnesses. Journal of Pediatrics, 1994, 125, 909-911.	1.8	85
72	Multicenter Comparison of Magnetic Resonance Imaging and Transcranial Doppler Ultrasonography in the Evaluation of the Central Nervous System in Children With Sickle Cell Disease. The American Journal of Pediatric Hematology/oncology, 2000, 22, 335-339.	1.3	83

#	Article	IF	Citations
73	Clinical Manifestations of Â-Thalassemia. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a011742-a011742.	6.2	82
74	Quality of Life in Patients with Thalassemia Intermedia Compared to Thalassemia Major. Annals of the New York Academy of Sciences, 2005, 1054, 457-461.	3.8	80
75	Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2003, 25, 629-634.	0.6	79
76	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753.	1.4	78
77	Newborn Screening for Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1996, 18, 36-41.	0.6	77
78	Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood, 2003, 101, 2865-2869.	1.4	75
79	Bone mineral density in children with sickle cell anemia. Pediatric Blood and Cancer, 2006, 47, 901-906.	1.5	74
80	Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin S level and reducing iron overload. Journal of Clinical Apheresis, 1999, 14, 122-125.	1.3	73
81	A pilot study of subcutaneous decitabine in Î²-thalassemia intermedia. Blood, 2011, 118, 2708-2711.	1.4	73
82	A potent oral Pâ€selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. American Journal of Hematology, 2012, 87, 536-539.	4.1	72
83	New therapies in sickle cell disease. Lancet, The, 2002, 360, 629-631.	13.7	70
84	Mycoplasma Disease and Acute Chest Syndrome in Sickle Cell Disease. Pediatrics, 2003, 112, 87-95.	2.1	70
85	GROWTH RETARDATION IN SICKLE-CELL DISEASE TREATED BY NUTRITIONAL SUPPORT. Lancet, The, 1985, 325, 903-906.	13.7	69
86	Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells, Molecules, and Diseases, 2013, 50, 99-104.	1.4	69
87	Core decompression in avascular necrosis of the hip in sickle-cell disease. , 1996, 52, 103-107.		67
88	Hydroxyurea in Children with Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1998, 20, 26-31.	0.6	67
89	Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825.	3.5	67
90	A pilot study of the shortâ€term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. British Journal of Haematology, 2011, 153, 655-663.	2.5	67

#	Article	IF	Citations
91	Longâ€term safety and efficacy of deferasirox (Exjade^{Â®}) for up to 5â€ƒyears in transfusional ironâ€overloaded patients with sickle cell disease. British Journal of Haematology, 2011, 154, 387-397.	2.5	67
92	Alpha thalassemia majorâ€"new mutations, intrauterine management, and outcomes. Hematology American Society of Hematology Education Program, 2009, 2009, 35-41.	2.5	66
93	Surgery in patients with hemoglobin SC disease. , 1998, 57, 101-108.		65
94	Central venous catheter complications in sickle cell disease. American Journal of Hematology, 2002, 69, 103-108.	4.1	64
95	Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone, 2008, 43, 162-168.	2.9	64
96	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436.	4.1	63
97	Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. Transfusion, 2012, 52, 2671-2676.	1.6	62
98	Pulmonary hypertension in thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 205-213.	3.8	61
99	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2021, 8, e323-e333.	4.6	61
100	Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood, 2000, 95, 3562-3567.	1.4	59
101	Fetal haemoglobin augmentation in E/beta0 thalassaemia: clinical and haematological outcome. British Journal of Haematology, 2005, 131, 378-388.	2.5	59
102	Pulmonary hypertension and NO in sickle cell. Blood, 2010, 116, 852-854.	1.4	59
103	Sickle Cell Disease in a Patient with Sickle Cell Trait and Compound Heterozygosity for Hemoglobin S and Hemoglobin Quebecâ€"Chori. New England Journal of Medicine, 1991, 325, 1150-1154.	27.0	58
104	Deferoxamine treatment during pregnancy: Is it harmful?. American Journal of Hematology, 1999, 60, 24-26.	4.1	57
105	Changing Outcome of Homozygous Î±-Thalassemia: Cautious Optimism. The American Journal of Pediatric Hematology/oncology, 2000, 22, 539-542.	1.3	57
106	Reproductive capacity in iron overloaded women with thalassemia major. Blood, 2011, 118, 2878-2881.	1.4	57
107	Sickle Cell Anemia and Related Hemoglobinopathies. Pediatric Clinics of North America, 1980, 27, 429-447.	1.8	56
108	PEROXIDATION, VITAMIN E, AND SICKLE-CELL ANEMIA. Annals of the New York Academy of Sciences, 1982, 393, 323-335.	3.8	56

#	Article	IF	Citations
109	Bone and Joint Disease in Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2005, 19, 929-941.	2.2	56
110	Patient-Reported Outcomes of Deferasirox (ExjadeÂ®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Acta Haematologica, 2008, 119, 133-141.	1.4	56
111	Assessment of Sickle Cell Pain in Children and Young Adults Using the Adolescent Pediatric Pain Tool. Journal of Pain and Symptom Management, 2002, 23, 114-120.	1.2	55
112	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood, 2011, 118, 3794-3802.	1.4	55
113	Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. Journal of the National Medical Association, 2006, 98, 704-10.	0.8	55
114	Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Annals of the New York Academy of Sciences, 2010, 1202, 180-187.	3.8	54
115	Mechanisms of plasma nonâ€transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. British Journal of Haematology, 2014, 167, 692-696.	2.5	54
116	Clinician Assessment for Acute Chest Syndrome in Febrile Patients With Sickle Cell Disease: Is It Accurate Enough?. Annals of Emergency Medicine, 1999, 34, 64-69.	0.6	53
117	Chlamydia pneumoniae and Acute Chest Syndrome in Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2003, 25, 46-55.	0.6	52
118	Variability in Hepatic Iron Concentration in Percutaneous Needle Biopsy Specimens From Patients With Transfusional Hemosiderosis. American Journal of Clinical Pathology, 2005, 123, 146-152.	0.7	52
119	Dose-Escalation Study of ICA-17043 in Patients with Sickle Cell Disease. Pharmacotherapy, 2006, 26, 1557-1564.	2.6	51
120	Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. British Journal of Haematology, 2008, 140, 104-112.	2.5	50
121	Universal Screening for Hemoglobinopathies Using High-Performance Liquid Chromatography: Clinical Results of 2.2 Million Screens. European Journal of Human Genetics, 1994, 2, 262-271.	2.8	50
122	Tonsillectomy, Adenoidectomy, and Myringotomy in Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1999, 21, 129-135.	0.6	49
123	Advances in the treatment of alpha-thalassemia. Blood Reviews, 2012, 26, S31-S34.	5.7	49
124	Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. , 1999, 62, 221-227.		48
125	Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatric Blood and Cancer, 2005, 44, 500-507.	1.5	48
126	Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Current Medical Research and Opinion, 2016, 32, 191-204.	1.9	48

#	Article	IF	Citations
127	Safety and efficacy of pegylated interferon Â-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica, 2008, 93, 1247-1251.	3.5	47
128	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38.	3.3	47
129	HLA type and risk of alloimmunization in sickle cell disease. American Journal of Hematology, 2009, 84, 462-464.	4.1	46
130	Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: Effects of continued penicillin prophylaxis. Journal of Pediatrics, 1996, 129, 828-835.	1.8	45
131	Longitudinal Changes in Ferritin During Chronic Transfusion: A Report From the Stroke Prevention Trial in Sickle Cell Anemia (STOP). Journal of Pediatric Hematology/Oncology, 2002, 24, 284-290.	0.6	45
132	Caregiving time in sickle cell disease: Psychological effects in maternal caregivers. Pediatric Blood and Cancer, 2007, 48, 64-71.	1.5	45
133	Simvastatin reduces vasoâ€occlusive pain in sickle cell anaemia: a pilot efficacy trial. British Journal of Haematology, 2017, 177, 620-629.	2.5	45
134	Iron Metabolism and Iron Chelation in Sickle Cell Disease. Acta Haematologica, 2009, 122, 174-183.	1.4	44
135	Use of Hydroxyurea in Children Ages 2 to 5 Years With Sickle Cell Disease. The American Journal of Pediatric Hematology/oncology, 2000, 22, 330-334.	1.3	44
136	DETECTION AND ASSESSMENT OF STROKE IN PATIENTS WITH SICKLE CELL DISEASE: Neuropsychological Functioning and Magnetic Resonance Imaging. Pediatric Hematology and Oncology, 2008, 25, 409-421.	0.8	42
137	Clinical Evaluation of Avascular Necrosis in Patients With Sickle Cell Disease: Childrenâ€™s Hospital Oakland Hip Evaluation Scaleâ€"A Modification of the Harris Hip Score. Archives of Physical Medicine and Rehabilitation, 2005, 86, 1369-1375.	0.9	41
138	Severe Sickle Cell Diseaseâ€"Pathophysiology and Therapy. Biology of Blood and Marrow Transplantation, 2010, 16, S64-S67.	2.0	41
139	Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. American Journal of Clinical Nutrition, 2013, 98, 960-971.	4.7	41
140	PHYSICAL THERAPY ALONE COMPARED WITH CORE DECOMPRESSION AND PHYSICAL THERAPY FOR FEMORAL HEAD OSTEONECROSIS IN SICKLE CELL DISEASE. Journal of Bone and Joint Surgery - Series A, 2006, 88, 2573-2582.	3.0	41
141	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367.	3.5	40
142	Emergency department utilization by Californians with sickle cell disease, 2005â€"2014. Pediatric Blood and Cancer, 2017, 64, e26390.	1.5	40
143	Phase Ib clinical trial of starchâ€conjugated deferoxamine (40SD02): a novel longâ€acting iron chelator. British Journal of Haematology, 2007, 138, 374-381.	2.5	39
144	Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatric Blood and Cancer, 2008, 50, 319-324.	1.5	39

#	Article	IF	Citations
145	Inadequate Dietary Intake in Patients with Thalassemia. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 980-990.	0.8	39
146	Population based surveillance in sickle cell disease: Methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatric Blood and Cancer, 2014, 61, 2271-2276.	1.5	39
147	Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. Prenatal Diagnosis, 2016, 36, 1242-1249.	2.3	39
148	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. British Journal of Haematology, 2000, 111, 498-500.	2.5	38
149	Chronic organ failure in adult sickle cell disease. Hematology American Society of Hematology Education Program, 2017, 2017, 435-439.	2.5	38
150	Can peak systolic velocities be used for prediction of stroke in sickle cell anemia?. Pediatric Radiology, 2005, 35, 66-72.	2.0	37
151	A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica, 2011, 96, 521-525.	3.5	37
152	Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease. JAMA Network Open, 2020, 3, e2010874.	5.9	37
153	Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian Journal of Medical Research, 2011, 134, 522-31.	1.0	37
154	Consensus document for transfusion-related iron overload. Seminars in Hematology, 2001, 38, 2-4.	3.4	36
155	Advances in clinical research in sickle cell disease. British Journal of Haematology, 2008, 141, 346-356.	2.5	36
156	Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone, 2011, 48, 1305-1312.	2.9	36
157	Validation and reliability of a diseaseâ€specific quality of life measure (the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 267 Td (<sc Haematology, 2014, 164, 431-437.	2.5	36
158	Umbilical cord blood stem cells: Application for the treatment of patients with hemoglobinopathies. Journal of Pediatrics, 1997, 130, 695-703.	1.8	35
159	Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Twoâ€year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology, 2013, 88, 1068-1073.	4.1	35
160	Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell disease. Blood, 2001, 97, 3401-3404.	1.4	34
161	HbE/Î²-Thalassemia: Basis of Marked Clinical Diversity. Hematology/Oncology Clinics of North America, 2010, 24, 1055-1070.	2.2	34
162	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	3.2	33

#	Article	IF	Citations
163	Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin. Journal of Pediatrics, 1998, 132, 871-873.	1.8	32
164	IRON HOMEOSTASIS DURING TRANSFUSIONAL IRON OVERLOAD IN Î²-THALASSEMIA AND SICKLE CELL DISEASE: Changes in Iron Regulatory Protein, Hepcidin, and Ferritin Expression. Pediatric Hematology and Oncology, 2007, 24, 237-243.	0.8	31
165	Suggested Guidelines for the Treatment of Children with Sickle Cell Anemia. Hematology/Oncology Clinics of North America, 1987, 1, 483-501.	2.2	30
166	A phase 1/2 trial of HQKâ€1001, an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology, 2012, 87, 1017-1021.	4.1	30
167	LIVER TRANSPLANTATION IN A CHILD WITH SICKLE CELL ANEMIA. Transplantation, 1995, 59, 1490-1492.	1.0	29
168	Sickle-cell disease not identified by newborn screening because of prior transfusion. Journal of Pediatrics, 2000, 136, 248-250.	1.8	29
169	Pain in thalassaemia: the effects of age on pain frequency and severity. British Journal of Haematology, 2013, 160, 680-687.	2.5	29
170	A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. British Journal of Haematology, 2001, 114, 718-720.	2.5	28
171	Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion, 2008, 48, 1971-1980.	1.6	28
172	Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia. Journal of Pediatrics, 2010, 157, 641-647.e2.	1.8	28
173	Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors. Blood Cells, Molecules, and Diseases, 2018, 70, 66-77.	1.4	28
174	Influence of Penicillin Prophylaxis on Antimicrobial Resistance in Nasopharyngeal S. Pneumoniae among Children with Sickle Cell Anemia. The American Journal of Pediatric Hematology/oncology, 1997, 19, 327-333.	1.3	28
175	Acute chest syndrome and sickle cell disease. Current Opinion in Hematology, 1998, 5, 89-92.	2.5	27
176	Treatment of Classic Pantothenate Kinaseâ€“Associated Neurodegeneration with Deferiprone and Intrathecal Baclofen. American Journal of Physical Medicine and Rehabilitation, 2013, 92, 728-733.	1.4	27
177	The natural history of sickle cell disease. Current Opinion in Pediatrics, 1998, 10, 49-52.	2.0	26
178	Vitamin C Deficiency in Patients with Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 1990, 12, 262.	0.6	26
179	Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood, 2000, 96, 3276-3278.	1.4	26
180	Inadequate erythroid response to hypoxia in cystic fibrosis. Journal of Pediatrics, 1984, 105, 15-21.	1.8	25

#	Article	IF	Citations
181	Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. American Journal of Hematology, 2013, 88, 771-773.	4.1	25
182	Fertility in transfusionâ€dependent thalassemia men: Effects of iron burden on the reproductive axis. American Journal of Hematology, 2015, 90, E190-2.	4.1	25
183	In utero hematopoietic cell transplantation for hemoglobinopathies. Frontiers in Pharmacology, 2014, 5, 278.	3.5	25
184	Survival and causes of death in 2,033 patients with non-transfusion-dependent Î²-thalassemia. Haematologica, 2021, 106, 2489-2492.	3.5	25
185	Hemoglobin Hâ€constant spring in North America: An alpha thalassemia with frequent complications. American Journal of Hematology, 2009, 84, 759-761.	4.1	24
186	The role of fetal hemoglobinâ€“enhancing agents in thalassemia. Seminars in Hematology, 2004, 41, 17-22.	3.4	23
187	The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatric Blood and Cancer, 2013, 60, 1507-1512.	1.5	23
188	Emerging â€˜Aâ€™ therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology American Society of Hematology Education Program, 2012, 2012, 271-275.	2.5	23
189	The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. Immunohematology, 2012, 28, 20-23.	0.2	23
190	PULMONARY COMPLICATIONS. Hematology/Oncology Clinics of North America, 1996, 10, 1275-1287.	2.2	22
191	The mediating effects of family functioning on psychosocial outcomes in healthy siblings of children with sickle cell disease. Pediatric Blood and Cancer, 2011, 57, 1055-1061.	1.5	22
192	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	2.5	22
193	Fertility and Pregnancy in Women with Transfusion-Dependent Thalassemia. Hematology/Oncology Clinics of North America, 2018, 32, 297-315.	2.2	22
194	Outcomes of Preimplantation Genetic Diagnosis Therapy in Treatment of Î²-Thalassemia: A Retrospective Analysis. Annals of the New York Academy of Sciences, 2005, 1054, 500-503.	3.8	21
195	Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. Blood, 1997, 89, 1787-1792.	1.4	21
196	A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat Î²-Thalassemia Intermedia. Blood, 2010, 116, 2078-2078.	1.4	21
197	Hemoglobin E-Î²-Thalassemia: Progress Report from the International Study Group. Annals of the New York Academy of Sciences, 2005, 1054, 33-39.	3.8	20
198	Treatment of Hepatitis C Virus Infection in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 290-299.	3.8	20

#	Article	IF	Citations
199	Transfusion and Chelation Practices in Sickle Cell Disease: A Regional Perspective. Pediatric Hematology and Oncology, 2011, 28, 124-133.	0.8	20
200	Transfusion practices and complications in thalassemia. Transfusion, 2018, 58, 2826-2835.	1.6	20
201	Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, 2000, 96, 3369-3373.	1.4	20
202	Pain over time and its effects on life in thalassemia. American Journal of Hematology, 2013, 88, 939-943.	4.1	19
203	Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2022, 97, .	4.1	19
204	Ototoxicity in Hemoglobinopathy Patients Chelated with Desferrioxamine. Journal of Pediatric Hematology/Oncology, 1996, 18, 42-45.	0.6	18
205	Pancytopenia Induced by Hypothermia. Journal of Pediatric Hematology/Oncology, 2002, 24, 681-684.	0.6	18
206	Deferiprone and hepatic fibrosis. Blood, 2003, 101, 5089-5091.	1.4	18
207	Hydroxycarbamideâ€induced changes in E/beta thalassemia red blood cells. American Journal of Hematology, 2008, 83, 842-845.	4.1	18
208	The transfusion management of beta thalassemia in the United States. Transfusion, 2021, 61, 3027-3039.	1.6	18
209	Outreach Strategies for Southeast Asian Communities: Experience, Practice, and Suggestions for Approaching Southeast Asian Immigrant and Refugee Communities to Provide Thalassemia Education and Trait Testing. The American Journal of Pediatric Hematology/oncology, 2000, 22, 588-592.	1.3	17
210	Utility of Holter Electrocardiogram in Iron-Overloaded Hemoglobinopathies. Annals of the New York Academy of Sciences, 2005, 1054, 476-480.	3.8	17
211	Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia. Pediatrics, 2008, 121, 1253-1256.	2.1	17
212	Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia. Magnetic Resonance Imaging, 2010, 28, 363-371.	1.8	17
213	Fertility potential in thalassemia major women: current findings and future diagnostic tools. Annals of the New York Academy of Sciences, 2010, 1202, 226-230.	3.8	17
214	Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product). Blood, 2015, 126, 201-201.	1.4	17
215	Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. Blood, 2016, 128, 1175-1175.	1.4	17
216	Psychosocial and behavioral outcomes in children with sickle cell disease and their healthy siblings. Journal of Behavioral Medicine, 2008, 31, 506-516.	2.1	16

#	Article	IF	Citations
217	Approaches to Transfusion Therapy and Iron Overload in Patients with Sickle Cell Disease: Results of an International Survey. Pediatric Hematology and Oncology, 2011, 28, 37-42.	0.8	16
218	Longâ€term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5Âyear observational study (ENTRUST). Pediatric Blood and Cancer, 2017, 64, e26507.	1.5	16
219	Pulmonary hypertension in hemolytic anemias. F1000 Medicine Reports, 2010, 2, .	2.9	16
220	Darbepoetin alfa for the treatment of anaemia in alphaâ€•or betaâ€•thalassaemia intermedia syndromes. British Journal of Haematology, 2011, 154, 281-284.	2.5	15
221	Epidemiologic and clinical characteristics of nontransfusionâ€dependent thalassemia in the United States. Pediatric Blood and Cancer, 2018, 65, e27067.	1.5	15
222	Single and Combination Drug Therapy for Fetal Hemoglobin Augmentation in Hemoglobin E-Î²0-Thalassemia: Considerations for Treatment. Annals of the New York Academy of Sciences, 2005, 1054, 250-256.	3.8	14
223	Measuring Chromosome Breaks in Patients with Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 439-444.	3.8	14
224	A Simple Model to Assess and Improve Adherence to Iron Chelation Therapy with Deferoxamine in Patients with Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 486-491.	3.8	14
225	Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy. Annals of Hematology, 2014, 93, 1139-1148.	1.8	14
226	Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology American Society of Hematology Education Program, 2012, 2012, 271-5.	2.5	14
227	Bone disease in Î²-thalassaemia. Lancet, The, 1999, 354, 881-882.	13.7	13
228	Diseases of iron metabolism. Pediatric Clinics of North America, 2002, 49, 893-909.	1.8	13
229	Hematologic problems in immigrants from Southeast Asia. Hematology/Oncology Clinics of North America, 2004, 18, 1405-1422.	2.2	13
230	Voxelotor for the treatment of sickle cell disease. Expert Review of Hematology, 2021, 14, 253-262.	2.2	13
231	Transfusion Therapy: A Coming-of-Age Treatment for Patients With Sickle Cell Disease. The American Journal of Pediatric Hematology/oncology, 2001, 23, 197-202.	1.3	13
232	The Social Impact of Migration on Disease: Cooley's Anemia, Thalassemia, and New Asian Immigrants. Annals of the New York Academy of Sciences, 1998, 850, 509-511.	3.8	12
233	ELEVATED EXHALED CARBON MONOXIDE CONCENTRATION IN HEMOGLOBINOPATHIES AND ITS RELATION TO RED BLOOD CELL TRANSFUSION THERAPY. Pediatric Hematology and Oncology, 2010, 27, 112-121.	0.8	12
234	The effect of whole body vibration therapy on bone density in patients with thalassemia: A pilot study. American Journal of Hematology, 2012, 87, E76-9.	4.1	12

#	Article	IF	Citations
235	Effects of Red Blood Cell Transfusion on Resting Energy Expenditure in Adolescents with Sickle Cell Anemia. Journal of Pediatric Gastroenterology and Nutrition, 1999, 29, 127-131.	1.8	12
236	Transfusion practice for patients with sickle cell disease. Current Opinion in Hematology, 1999, 6, 432.	2.5	12
237	Novel influenza a (H1N1) viral infection in pediatric patients with sickle-cell disease. Pediatric Blood and Cancer, 2011, 56, 95-98.	1.5	11
238	Renal medullary carcinoma in an adolescent with sickle cell anemia. Pediatric Blood and Cancer, 2014, 61, 567-567.	1.5	11
239	Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study. Blood, 2020, 136, 31-32.	1.4	11
240	Preliminary Report: Hydroxyurea Produces Significant Clinical Response in Thalassemia Intermedia. Annals of the New York Academy of Sciences, 1998, 850, 461-462.	3.8	10
241	Education and employment status of children and adults with thalassemia in North America. Pediatric Blood and Cancer, 2010, 55, 678-683.	1.5	10
242	Application of Multiplex Ligation-Dependent Probe Amplification to Screen for Î²-Globin Cluster Deletions: Detection of Two Novel Deletions in a Multi Ethnic Population. Hemoglobin, 2013, 37, 241-256.	0.8	10
243	Influence of sickle cell disease on susceptibility to HIV infection. PLoS ONE, 2020, 15, e0218880.	2.5	10
244	Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2221-2230.	2.4	10
245	Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia in the Northstar (HGB-204) Study. Blood, 2019, 134, 4628-4628.	1.4	10
246	Long-Term Treatment with Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias.. Blood, 2007, 110, 2777-2777.	1.4	10
247	Deferasirox (ExjadeÂ®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. Blood, 2008, 112, 1420-1420.	1.4	10
248	Pulmonary Hypertension in Thalassemia: Association with Hemolysis, Arginine Metabolism Dysregulation, and a Hypercoagulable State. Advances in Pulmonary Hypertension, 2007, 6, 31-38.	0.1	10
249	Novel Therapeutic Approaches in Sickle Cell Disease. Hematology American Society of Hematology Education Program, 2002, 2002, 10-34.	2.5	9
250	Liver Ferritin Subunit Ratios in Neonatal Hemochromatosis. Pediatric Hematology and Oncology, 2003, 20, 229-235.	0.8	9
251	Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. Pediatric Blood and Cancer, 2010, 54, 148-150.	1.5	9
252	Lifespan care in SCD: Whom to transition, the patients or the health care system?. American Journal of Hematology, 2017, 92, 487-489.	4.1	9

#	Article	IF	Citations
253	Long-Term Efficacy and Safety with Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients.. Blood, 2007, 110, 2774-2774.	1.4	9
254	New therapies and approaches to transfusion in sickle cell disease in children. Current Opinion in Pediatrics, 1997, 9, 41-45.	2.0	8
255	PREVALENCE OF HFE MUTATIONS IN CALIFORNIA NEWBORNS. Pediatric Hematology and Oncology, 2006, 23, 507-516.	0.8	8
256	Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1â€“2):1â€“15.]. Hemoglobin, 2008, 32, 601-607.	0.8	8
257	Hemoglobin Hakkari: An autosomal dominant form of beta thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene. Pediatric Blood and Cancer, 2010, 54, 332-335.	1.5	8
258	Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: Single-institution experience. Pediatric Hematology and Oncology, 2017, 34, 100-106.	0.8	8
259	Iron Deficiency: Implications Before Anemia. Pediatrics in Review, 2021, 42, 11-20.	0.4	8
260	Candidate Gene Polymorphisms and Their Association with TCD Velocities in Children with Sickle Cell Disease.. Blood, 2007, 110, 429-429.	1.4	8
261	Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia.. Blood, 2009, 114, 2021-2021.	1.4	8
262	Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 2000, 96, 76-79.	1.4	8
263	Primary HBB gene mutation severity and longâ€term outcomes in a global cohort of Î²â€thalassaemia. British Journal of Haematology, 2022, 196, 414-423.	2.5	8
264	Current treatment of sickle cell disease. Current Problems in Pediatrics, 1980, 10, 1-64.	1.1	7
265	Chart Card: Feasibility of a Tool for Improving Emergency Department Care in Sickle Cell Disease. Journal of the National Medical Association, 2010, 102, 1017-1024.	0.8	7
266	Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403.	2.5	7
267	Sickle cell anemia, thalassemia, and congenital hemolytic anemias. , 2016, , 126-143.		7
268	A complication risk score to evaluate clinical severity of thalassaemia syndromes. British Journal of Haematology, 2021, 192, 626-633.	2.5	7
269	Time to rethink haemoglobin threshold guidelines in sickle cell disease. British Journal of Haematology, 2021, 195, 518-522.	2.5	7
270	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. Blood, 2006, 108, 1208-1208.	1.4	7

#	Article	IF	Citations
271	Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2013, 122, 988-988.	1.4	7
272	Report of Proceedings: 1999 International Conference on E-Î² Thalassemia. The American Journal of Pediatric Hematology/oncology, 2000, 22, 550.	1.3	6
273	Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. Journal of Intensive Care Medicine, 2000, 15, 159-166.	2.8	6
274	The Arginine-to-Ornithine Ratio: Biomarker of Arginase Activity and Predictor of Mortality in Sickle Cell Disease.. Blood, 2004, 104, 237-237.	1.4	6
275	Consensus statement for the perinatal management of patients with Î± thalassemia major. Blood Advances, 2021, 5, 5636-5639.	5.2	6
276	Stem Cell Transplantation for Sickle Cell Disease: Can We Reduce the Toxicity?. Fetal and Pediatric Pathology, 2001, 20, 73-86.	0.3	5
277	Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients. AIDS Research and Human Retroviruses, 2013, 29, 1006-1009.	1.1	5
278	Vincristine-induced anemia in hereditary spherocytosis. Experimental Biology and Medicine, 2019, 244, 850-854.	2.4	5
279	Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study. Blood, 2019, 134, 2313-2313.	1.4	5
280	Collaborative Data Project [C-DATA] of the Comprehensive Sickle Cell Centers Program.. Blood, 2006, 108, 1200-1200.	1.4	5
281	Long-Term Efficacy and Safety of Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 3395-3395.	1.4	5
282	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
283	Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease.. Blood, 2009, 114, 573-573.	1.4	5
284	Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia. Haematologica, 2021, 106, 1740-1744.	3.5	5
285	Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. Blood, 2021, 138, 576-576.	1.4	5
286	In Utero Stem Cell Transplantation in Patients with Alpha Thalassemia Major: Interim Results of a Phase 1 Clinical Trial. Blood, 2020, 136, 1-1.	1.4	5
287	Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study. Complementary Therapies in Medicine, 2022, 64, 102803.	2.7	5
288	Anemia associated with rheumatoid arthritis. Journal of Pediatrics, 1979, 94, 678.	1.8	4

#	Article	IF	Citations
289	Acute Chest Syndrome in Sickle Cell Disease: Pathophysiology and Management. Journal of Intensive Care Medicine, 2000, 15, 159-166.	2.8	4
290	Dietary nonheme iron is equally bioavailable from ferritin or ferrous sulfate in thalassemia intermedia. Pediatric Hematology and Oncology, 2017, 34, 455-467.	0.8	4
291	Core decompression in avascular necrosis of the hip in sickleâ€cell disease. American Journal of Hematology, 1996, 52, 103-107.	4.1	4
292	Serum Ferritin a Predictor of Iron Overload in Patients with Thalassemia and Sickle Cell Disease?.. Blood, 2004, 104, 3789-3789.	1.4	4
293	Safety and Efficacy of Peginterferon Alfa-2a and Ribavirin for Hepatitis C in Thalassemia.. Blood, 2006, 108, 558-558.	1.4	4
294	A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease. Blood, 2010, 116, 3221-3221.	1.4	4
295	Baseline Characteristics of Patients with Sickle Cell Disease in An Ongoing 5-Year, Prospective, Noninterventional Registry Trial. Blood, 2011, 118, 1060-1060.	1.4	4
296	Anemia in the Newborn Period. Pediatric Annals, 1979, 8, 10-37.	0.8	4
297	Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in Î²-Thalassemia. Blood, 2015, 126, 950-950.	1.4	4
298	An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. British Journal of Haematology, 2022, 196, 380-389.	2.5	4
299	Unstable Hemoglobins, Hemoglobins with Altered Oxygen Affinity, and M-Hemoglobins. Pediatric Clinics of North America, 1980, 27, 421-428.	1.8	3
300	Identification of Three Novel Hb F Variants: Hb F-Hayward [^GÎ³1(NA1)Glyâ†'Asp, GGT>GAT], Hb F-Chori-I [^AÎ³^T16(A13)Glyâ†'Asp, GGC>GAC] and Hb F-Chori-II [^AÎ³^I29(B11)Glyâ†'Glu, GGA>GAA]. Hemoglobin, 2012, 36, 305-309.	0.8	3
301	Emerging Therapy in Hemoglobinopathies: Lessons from the Past and Optimism for the Future. Hematology/Oncology Clinics of North America, 2014, 28, xiii-xviii.	2.2	3
302	Is the Medical Home for Adult Patients with Sickle Cell Disease a Reality or an Illusion?. Hemoglobin, 2015, 39, 130-133.	0.8	3
303	The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group. American Journal of Hematology, 1999, 62, 129-138.	4.1	3
304	Erythrocytapheresis for chronically transfused children with sickle cell disease: An effective method for maintaining a low hemoglobin S level and reducing iron overload. Journal of Clinical Apheresis, 1999, 14, 122-125.	1.3	3
305	Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia Following Completion of the Northstar HGB-204 Study. Blood, 2018, 132, 167-167.	1.4	3
306	Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. Blood, 2018, 132, 505-505.	1.4	3

#	Article	IF	Citations
307	Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study. Blood, 2019, 134, 1020-1020.	1.4	3
308	Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis. Blood, 2020, 136, 19-19.	1.4	3
309	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. Blood, 2009, 114, 2016-2016.	1.4	3
310	A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy. Blood, 2011, 118, 1082-1082.	1.4	3
311	Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better!.. Blood, 2012, 120, 2101-2101.	1.4	3
312	NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial. Blood, 2014, 124, 2718-2718.	1.4	3
313	Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. Thalassemia Reports, 2022, 12, 14-23.	0.5	3
314	The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells. Complementary Therapies in Medicine, 2022, 70, 102856.	2.7	3
315	Preface to Cooley's Anemia: Ninth Symposium. Annals of the New York Academy of Sciences, 2010, 1202, ix-x.	3.8	2
316	Stroke recurrence in adult sickle cell patients: it is time for action!. Transfusion, 2016, 56, 1001-1004.	1.6	2
317	Hemoglobinopathies. , 2011, , 1662-1677.e1.		2
318	Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress. Blood, 2019, 134, 2249-2249.	1.4	2
319	Biotin-Labeled RBC Survival in Thalassemia and Impact of Treatment.. Blood, 2004, 104, 3616-3616.	1.4	2
320	Barriers to Deferoxamine Adherence for Adults with Sickle Cell Disease.. Blood, 2004, 104, 3760-3760.	1.4	2
321	Assessing Compliance to Iron Chelation Therapy in Patients with Thalassemia.. Blood, 2004, 104, 3787-3787.	1.4	2
322	Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in Î²-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.. Blood, 2005, 106, 3598-3598.	1.4	2
323	MRI Assessment of Pituitary Iron and Volume in Thalassemia, and Relation to Hypothalamic-Pituitary-Gonadal Axis Function (HPG): A Feasibility Study.. Blood, 2006, 108, 1778-1778.	1.4	2
324	The Effect of Short-Term Simvastatin On Markers of Vascular Dysfunction in Patients with Sickle Cell Disease (SCD).. Blood, 2009, 114, 260-260.	1.4	2

#	Article	IF	Citations
325	Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. Blood, 2010, 116, 4269-4269.	1.4	2
326	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	1.4	2
327	Liver Iron Measurement by SQUID Compared to Liver Biopsy.. Blood, 2006, 108, 3826-3826.	1.4	2
328	The Effect of Thalassemia and Other RBC Hemolytic Disorders and Splenectomy on the Frequency of Pulmonary Hypertension. Blood, 2010, 116, 2077-2077.	1.4	2
329	Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia. Blood, 2012, 120, 995-995.	1.4	2
330	Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy. Blood, 2013, 122, 3450-3450.	1.4	2
331	Systemic Biomarkers Show Elevated Oxidative Stress and Chronic Inflammation in Two Disorders of Neurodegeneration with Brain Iron Accumulation (NBIA). Blood, 2017, 130, 943-943.	1.4	2
332	Risks Factors And Mortality Associated With Doppler-Defined-Pulmonary Hypertension In Thalassemia Major: A Report From The Thalassemia Clinical Research Network Longitudinal Cohort Study. , 2011, , .		1
333	Response to "Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.. Haematologica, 2014, 99, e19-e19.	3.5	1
334	Evaluation of Mandible Fractures in Patients With Sickle Cell Anemiaâ€"A Nationwide Study. Journal of Oral and Maxillofacial Surgery, 2019, 77, 1418-1422.	1.2	1
335	Pulmonary Hypertension in Sickle Cell Disease: A Common Complication for Both Adults and Children.. Blood, 2004, 104, 1666-1666.	1.4	1
336	Progression of Organ Dysfunction in Iron Overloaded Patients with Î² Thalassemia and Sickle Cell Disease.. Blood, 2004, 104, 1683-1683.	1.4	1
337	Progression of Avascular Necrosis of the Hip in Sickle Cell Disease: 2 Year Follow-Up of Randomized Trial of Aggressive Physical Therapy and Hip Coring Decompression.. Blood, 2004, 104, 1685-1685.	1.4	1
338	An Effective Program to Resolve Ambiguous Results from State Newborn Hemoglobinopathy Screening.. Blood, 2004, 104, 3563-3563.	1.4	1
339	Abnormal Pulmonary Function in Adults and Children with Sickle Cell Disease.. Blood, 2005, 106, 2319-2319.	1.4	1
340	Leukocyte Apoptosis and Inflammation in Iron-Overloaded Patients with Sickle Cell Disease or Î²-Thalassemia: A Mechanism for Increased Stroke and Disease Severity in Sickle Cell Disease.. Blood, 2006, 108, 1233-1233.	1.4	1
341	Long-Term Safety and Efficacy of Deferasirox (ExjadeÂ®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. Blood, 2010, 116, 845-845.	1.4	1
342	Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). Blood, 2011, 118, 340-340.	1.4	1

#	Article	IF	Citations
343	Innate Immune Cell Expression of Pattern Recognition Receptors From Î²-Thalassemia Patients During Intensive Combination Chelation Therapy. Blood, 2012, 120, 1025-1025.	1.4	1
344	Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2â€“<6 Years At Enrollment.. Blood, 2012, 120, 2125-2125.	1.4	1
345	Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States. Blood, 2015, 126, 3279-3279.	1.4	1
346	Quality of Life in Patients with Thalassemia.. Blood, 2004, 104, 3786-3786.	1.4	1
347	Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease.. Blood, 2006, 108, 788-788.	1.4	1
348	Emergency Room Utilization by California Sickle Cell Patients During Pediatric to Adult Care Transition. Blood, 2010, 116, 254-254.	1.4	1
349	Renal Medullary Carcinoma in an Adolescent with Homozygous Hemoglobin SS. Blood, 2012, 120, 4774-4774.	1.4	1
350	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. Blood, 2012, 120, 2122-2122.	1.4	1
351	Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO) Tj ETQq1 1 0.784314 rgBT /Over	1.4	1
352	Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial. Blood, 2014, 124, 4890-4890.	1.4	1
353	Impact of Immigration and Migration on Thalassemia Surveillance in California, 2004-2008. Blood, 2014, 124, 4855-4855.	1.4	1
354	Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD). Blood, 2018, 132, 162-162.	1.4	1
355	Development of a Severity Score System for Thalassemia Syndromes. Blood, 2019, 134, 2225-2225.	1.4	1
356	Anterior Pituitary Volume in Patients with Transfusion Dependent Anemias: Volumetric Approaches and Relation to Pituitary MRIâ€˜R2. Clinical Neuroradiology, 2021, , 1.	1.9	1
357	Letter to the editor. Journal of Adolescent Health Care: Official Publication of the Society for Adolescent Medicine, 1988, 9, 87.	0.3	0
358	Editorial [Hot Topic:Genetic Disorders of Hemoglobin: Sickle Cell Anemia and Thalassemia (Guest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2008, 8, 591-591.	1.3	0
359	Metabolic Fate Of Oral Glutamine Supplementation Within Plasma And Erythrocytes Of Patients With Sickle Cell Disease And Pulmonary Hypertension: Preliminary Pharmacokinetics Results. , 2011, , .		0
360	Safety of deferasirox in sickle cell disease patients with coâ€existing liver impairment â€“ response to <scp>S</scp>inakos etÂal. British Journal of Haematology, 2012, 157, 506-507.	2.5	0

#	Article	IF	Citations
361	Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood, 2000, 95, 3562-3567.	1.4	0
362	Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.. Blood, 2004, 104, 3613-3613.	1.4	0
363	Pulmonary Hypertension: A Common Complication in Thalassemia.. Blood, 2004, 104, 3612-3612.	1.4	0
364	Toxic Unbound Iron and Membrane Injury in b-Thalassemia and Sickle Cell Disease: Elevated Non-Transferrin Bound Iron (NTBI) and Malondialdehyde (MDA).. Blood, 2004, 104, 3608-3608.	1.4	0
365	Utility of Holter Electrocardiogram Monitoring in Iron over Loaded Î² Thalassemia and Sickle Cell Disease.. Blood, 2004, 104, 3784-3784.	1.4	0
366	The Outcomes of Preimplantation Genetic Diagnosis Therapy in Treatment of Î² Thalassemia - a Retrospective Analysis.. Blood, 2004, 104, 3783-3783.	1.4	0
367	Pulmonary Hypertension in Thalassemia: Association with Platelet Activation and Hypercoagulable State.. Blood, 2004, 104, 3618-3618.	1.4	0
368	Early Hepatitis C Viral Response (EVR) to Peginterferon Alfa 2a and Ribavirin in Patients with Î² Thalassemia.. Blood, 2004, 104, 3624-3624.	1.4	0
369	Increased Chromosomal Breaks in Sickle Cell Disease as Evidenced by the Presence of Micronuclei in Erythrocytes.. Blood, 2005, 106, 3807-3807.	1.4	0
370	Hospitalization Rate and Regional Differences in Comprehensive Care in Transfused Patients with Sickle Cell Disease Compared to Thalassemia: A Report from the Multi-Center Study of Iron Overload.. Blood, 2005, 106, 3189-3189.	1.4	0
371	Dysregulated Arginine Metabolism and Elevated Arginase Activity in Thalassemia.. Blood, 2005, 106, 3644-3644.	1.4	0
372	High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience.. Blood, 2005, 106, 2706-2706.	1.4	0
373	Serum Ferritin and Liver Iron Concentration in Patients with Iron Overload.. Blood, 2005, 106, 3833-3833.	1.4	0
374	Quality of Life (QOL) in Sickle Cell Disease (SCD).. Blood, 2005, 106, 1324-1324.	1.4	0
375	Do Transfusions of Packed Red Blood Cells Decrease Renal Function in Adult Sickle Cell Patients?.. Blood, 2006, 108, 3793-3793.	1.4	0
376	Left Ventricular Dysfunction in Chronically Transused Patients with Sickle Cell Anemia and Thalassemia.. Blood, 2006, 108, 3745-3745.	1.4	0
377	Iron Overload in Acute Myelogenous Leukemia after Bone Marrow Transplantation.. Blood, 2006, 108, 5336-5336.	1.4	0
378	Bone Mineral Density in Transfusion Independent Thalassemia Patients.. Blood, 2006, 108, 3353-3353.	1.4	0

#	Article	IF	Citations
379	Neuropsychological (NP) Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adult Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 428-428.	1.4	0
380	High Frequency of Asthma, Sepsis and Acute Chest Syndrome in Children with Sickle Cell Disease and Pulmonary Hypertension.. Blood, 2007, 110, 3782-3782.	1.4	0
381	Leukocyte Apoptosis and Mitochondrial Dysfunction in Î²-Thalassemia Patients Treated with Deferasirox or Deferoxamine.. Blood, 2007, 110, 2773-2773.	1.4	0
382	Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications.. Blood, 2008, 112, 1880-1880.	1.4	0
383	Prolonged QTc in Sickle Cell Disease: A Potential Risk Factor for Early Death?. Blood, 2008, 112, 2476-2476.	1.4	0
384	Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. Blood, 2008, 112, 3890-3890.	1.4	0
385	Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. Blood, 2008, 112, 1868-1868.	1.4	0
386	Iron Overload Diminishes the Effectiveness of the Innate Immune Response in Thalassemia Major: a Possible Mechanism for Increased Infection Risk.. Blood, 2009, 114, 4071-4071.	1.4	0
387	Heightened Sulfur Amino Acid Oxidation in Plasma and Erythrocytes in Î²-Thalassemia Major.. Blood, 2009, 114, 4065-4065.	1.4	0
388	A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload. Blood, 2010, 116, 2057-2057.	1.4	0
389	The Palatability and Tolerability of Deferasirox (ExjadeÂ®) Taken with Meals, Different Liquids, or Crushed and Added to Food. Blood, 2010, 116, 5155-5155.	1.4	0
390	A New Method of Hip Coring Decompression for the Treatment of Femoral Avascular Necrosis In Sickle Cell Disease: Perioperative Safety and Preliminary Efficacy Data. Blood, 2010, 116, 264-264.	1.4	0
391	Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). Blood, 2010, 116, 256-256.	1.4	0
392	Longitudinal Follow-up From Newborn Screening Reveals Deletional Hemoglobin H Disease and Hemoglobin H Constant Spring Disease Are Distinct Thalassemia Syndromes. Blood, 2010, 116, 4260-4260.	1.4	0
393	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
394	Effect of Short-Term Simvastatin Treatment on Endothelial Adhesion Molecules in Sickle Cell Disease: A Pilot Study. Blood, 2011, 118, 1070-1070.	1.4	0
395	Mental Health Symptoms, Quality of Life and Barriers to Accessing Health Care in Sickle Cell Disease. Blood, 2011, 118, 337-337.	1.4	0
396	Oxidative Stress and Reproductive Capacity in Iron Overload Thalassemia Major Women. Blood, 2011, 118, 2155-2155.	1.4	0

#	Article	IF	Citations
397	Evaluation of Moyamoya Disease in Sickle Cell Anemia Patients After Encephaloduroarteriosynangiosis. Blood, 2011, 118, 1059-1059.	1.4	0
398	12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial. Blood, 2012, 120, 1010-1010.	1.4	0
399	Tricuspid Regurgitant Jet Velocity (TRV), Biomarkers of Hemolysis, and Impact of Oxygen Therapy in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE). Blood, 2012, 120, 4752-4752.	1.4	0
400	Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. Blood, 2013, 122, 4690-4690.	1.4	0
401	Abnormal Reproductive Measures and Seminal Plasma Findings in Men With Thalassemia Major (TM) and Iron Overload. Blood, 2013, 122, 4707-4707.	1.4	0
402	The Role of Oxidation in Diseases of the Human Erythrocyte. , 1990, , 34-47.		0
403	Related Cord Blood Banking for Patients with Hemoglobinopathies. Pediatric Research, 1999, 45, 149A-149A.	2.3	0
404	Association of HLA Type with Risk of Cerebral Infarction in Children with Sickle Cell Disease. Pediatric Research, 1999, 45, 147A-147A.	2.3	0
405	Low Molecular Weight Heparin in Sickle Cell Disease. Pediatric Research, 1999, 45, 153A-153A.	2.3	0
406	Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential. Blood, 2014, 124, 4048-4048.	1.4	0
407	The Effects of Glutamine Supplementation on Markers of Autophagy and Apoptosis in Peripheral Blood Mononuclear Cells from Patients with Sickle Cell Disease. Blood, 2015, 126, 3412-3412.	1.4	0
408	NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial. Blood, 2015, 126, 2178-2178.	1.4	0
409	Sickle Cell Disease: Management of Complications. , 2016, , 75-87.		0
410	Threshold Ferritin Values to Predict Control of Liver Iron Burden in Thalassemia. Blood, 2016, 128, 4824-4824.	1.4	0
411	Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study. Blood, 2016, 128, 2470-2470.	1.4	0
412	Episodic Patterns of High Emergency Department Utilization Among Sickle Cell Disease Patients. Blood, 2016, 128, 316-316.	1.4	0
413	Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer. Blood, 2019, 134, 961-961.	1.4	0
414	A Pilot Adult Sickle Cell Hematology Clinic in California's Inland Empire Improves Patient Outcome. Blood, 2019, 134, 3470-3470.	1.4	0

#	Article	IF	Citations
415	Three Distinct Groups of Phenotype Severity in Beta-Thalassemia. Blood, 2020, 136, 15-16.	1.4	0
416	Differential Acetone Extraction of Total and Hemoprotein-Unbound Heme to Quantify Heme Binding Capacity of Plasma in Patients with Sickle Cell Disease: The Role of Heme Scavengers. Blood, 2020, 136, 15-15.	1.4	0